{"id":"dfl24498","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DFL24498 is an investigational small molecule developed by Dompé Farmaceutici for oncology indications. As a kinase inhibitor in Phase 3 development, it likely works by blocking intracellular signaling pathways that drive cancer cell proliferation and survival, though the specific molecular target has not been widely disclosed in public literature.","oneSentence":"DFL24498 is a tyrosine kinase inhibitor targeting specific oncogenic pathways in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:51.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":"Atopic Keratoconjunctivitis","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DFL24498","genericName":"DFL24498","companyName":"Dompé Farmaceutici S.p.A","companyId":"domp-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}